Cytokinetics(CYTK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CYTK Cytokinetics

盘前交易 01-02 04:12:27 EST

63.54

+2.17

+3.54%

最高64.43	最低60.93	成交量198.08万
今开61.12	昨收61.37	日振幅5.70%
总市值77.69亿	流通市值75.67亿	总股本1.22亿
成交额1.26亿	换手率1.66%	流通股本1.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CYTK","market":"US","secType":"STK","nameCN":"Cytokinetics","latestPrice":63.54,"timestamp":1767214800000,"preClose":61.37,"halted":0,"volume":1980836,"delay":0,"floatShares":119088114,"shares":122264929,"eps":-6.317914,"marketStatus":"盘前交易","change":2.17,"latestTime":"01-02 04:12:27 EST","open":61.12,"high":64.43,"low":60.93,"amount":125841413.696856,"amplitude":0.057031,"askPrice":68,"askSize":20,"bidPrice":60,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-6.317914,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767364200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1083211200000,"exchange":"NASDAQ","adjPreClose":63.54,"postHourTrading":{"tag":"盘后","latestPrice":63.54,"preClose":63.54,"latestTime":"19:52 EST","volume":129008,"amount":8197189.4087,"timestamp":1767228725610},"volumeRatio":1.1241547188487382,"optionData":{"bulkOrders":[{"symbol":"CYTK","call":true,"expireDate":1768539600000,"strike":"75.0","timestamp":1767197094296,"price":0.7,"volume":2500,"amount":175000,"type":"+"}]},"impliedVol":0.6269,"impliedVolPercentile":0.4177},"requestUrl":"/m/hq/s/CYTK","defaultTab":"news","newsList":[{"id":"2593243985","title":"美股异动 | 阿夫凯泰片获批准上市 Cytokinetics(CYTK.US)大涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593243985","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593243985?lang=zh_cn&edition=full","pubTime":"2025-12-22 23:45","pubTimestamp":1766418320,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，Cytokinetics(CYTK.US)大涨超10%，续创年内新高，现报69.34美元。消息面上，近日，国家药品监督管理局通过优先审评审批程序，批准Cytokinetics, Incorporated申报的1类创新药阿夫凯泰片(商品名：星舒平)上市，该药用于治疗纽约心脏协会(NYHA)心功能分级II-III级的梗阻性肥厚型心肌病(HCM)成人患者，以改善运动能力和症状。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | 阿夫凯泰片获批准上市 Cytokinetics(CYTK.US)大涨超10%","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4505","BK4139","BK4585","BK4588","CYTK"],"gpt_icon":0},{"id":"1124007868","title":"Cytokinetics宣布Myqorzo™（Aficamten）获得FDA批准，用于治疗有症状的梗阻性肥厚型心肌病，以改善功能能力和症状","url":"https://stock-news.laohu8.com/highlight/detail?id=1124007868","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124007868?lang=zh_cn&edition=full","pubTime":"2025-12-20 05:00","pubTimestamp":1766178019,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布Myqorzo™（Aficamten）获得FDA批准，用于治疗有症状的梗阻性肥厚型心肌病，以改善功能能力和症状。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CYTK","BK4505","BK4585","BK4588"],"gpt_icon":0},{"id":"1146256720","title":"Cytokinetics宣布Myqorzo®（Aficamten）在中国获得NMPA批准，用于治疗梗阻性肥厚型心肌病患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1146256720","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146256720?lang=zh_cn&edition=full","pubTime":"2025-12-17 20:30","pubTimestamp":1765974616,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布Myqorzo®（Aficamten）在中国获得NMPA批准，用于治疗梗阻性肥厚型心肌病患者","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","CYTK","BK4505","BK4139"],"gpt_icon":0},{"id":"1117859396","title":"Cytokinetics宣布Myqorzo®（Aficamten）治疗阻塞性肥厚型心肌病获得积极的CHMP意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1117859396","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117859396?lang=zh_cn&edition=full","pubTime":"2025-12-12 21:45","pubTimestamp":1765547116,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布Myqorzo®（Aficamten）治疗阻塞性肥厚型心肌病获得积极的CHMP意见。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","CYTK","BK4505"],"gpt_icon":0},{"id":"1156065229","title":"异动解读 | Cytokinetics股价盘中大涨5.03%，分析师上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1156065229","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156065229?lang=zh_cn&edition=full","pubTime":"2025-11-12 01:44","pubTimestamp":1762883080,"startTime":"0","endTime":"0","summary":"生物制药公司Cytokinetics（CYTK）今日表现强劲，盘中大涨5.03%，引发投资者关注。\n\n消息面上，加拿大皇家银行资本市场分析师对Cytokinetics股票做出了积极评价。该机构将Cytokinetics的目标价从82美元上调至87美元，显示出对公司未来发展前景的看好。这一利好消息可能是推动股价上涨的主要原因。\n\nCytokinetics是一家专注于开发肌肉生物学新疗法的生物制药公司。分析师目标价的上调可能反映了市场对公司在研产品管线和未来增长潜力的信心增强。投资者应密切关注公司未来的临床试验结果和产品开发进展，这些因素可能会进一步影响股价表现。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CYTK"],"gpt_icon":0},{"id":"1109773369","title":"Cytokinetics在2025年肥厚性心肌病医学会科学会议及美国心脏协会科学会议上发布Maple-HCM的新增数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1109773369","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109773369?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:32","pubTimestamp":1762777931,"startTime":"0","endTime":"0","summary":"Cytokinetics在2025年肥厚性心肌病医学会科学会议及美国心脏协会科学会议上发布Maple-HCM的新增数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4588","CYTK","BK4585","BK4139"],"gpt_icon":0},{"id":"1159228276","title":"Cytokinetics宣布将于2025年在肥厚型心肌病医学协会科学会议和美国心脏协会科学会议上进行多场演讲","url":"https://stock-news.laohu8.com/highlight/detail?id=1159228276","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159228276?lang=zh_cn&edition=full","pubTime":"2025-10-31 19:31","pubTimestamp":1761910297,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布将于2025年在肥厚型心肌病医学协会科学会议和美国心脏协会科学会议上进行多场演讲","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4505","BK4588","CYTK"],"gpt_icon":0},{"id":"2568496296","title":"Cytokinetics将发行可转换优先票据筹集最多5.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568496296","media":"环球市场播报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568496296?lang=zh_cn&edition=full","pubTime":"2025-09-17 20:42","pubTimestamp":1758112920,"startTime":"0","endTime":"0","summary":"周三盘前，生物制药公司Cytokinetics（CYTK）上涨0.6%，此前该公司宣布，计划通过发行2031年到期的可转换优先票据筹集最多5.5亿美元资金。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-09-17/doc-infqvhrz2546128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CYTK","BK4585","BK4505","BK4588","BK4139"],"gpt_icon":0},{"id":"1181470114","title":"Cytokinetics宣布定价6.5亿美元扩大规模可转换优先票据发行；为2027年可转换票据部分进行再融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1181470114","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181470114?lang=zh_cn&edition=full","pubTime":"2025-09-17 11:46","pubTimestamp":1758080777,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布定价6.5亿美元扩大规模可转换优先票据发行；为2027年可转换票据部分进行再融资","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CYTK","BK4505","BK4585","BK4588"],"gpt_icon":0},{"id":"1107967207","title":"Cytokinetics——若Aficamten获FDA批准，公司仍预期其将具备差异化标签和风险缓解特征——SEC文件显示","url":"https://stock-news.laohu8.com/highlight/detail?id=1107967207","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107967207?lang=zh_cn&edition=full","pubTime":"2025-09-17 04:13","pubTimestamp":1758053597,"startTime":"0","endTime":"0","summary":"Cytokinetics——若Aficamten获FDA批准，公司仍预期其将具备差异化标签和风险缓解特征——SEC文件显示","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4505","CYTK","BK4585"],"gpt_icon":0},{"id":"1122526064","title":"Cytokinetics盘后股价下跌4.2%，宣布拟发行5.5亿美元可转换优先债券","url":"https://stock-news.laohu8.com/highlight/detail?id=1122526064","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122526064?lang=zh_cn&edition=full","pubTime":"2025-09-17 04:10","pubTimestamp":1758053451,"startTime":"0","endTime":"0","summary":"Cytokinetics盘后股价下跌4.2%，该公司宣布拟通过私募方式发行价值5.5亿美元的可转换优先债券。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CYTK","BK4505","BK4588","BK4585"],"gpt_icon":0},{"id":"2564388606","title":"百事涨5.8%激进投资机构Elliott Management已持有其40 亿美元股份。Cytokinetics涨27.","url":"https://stock-news.laohu8.com/highlight/detail?id=2564388606","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564388606?lang=zh_cn&edition=full","pubTime":"2025-09-02 21:30","pubTimestamp":1756819857,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0359201885.HKD","LU0463099449.HKD","LU0359201612.USD","LU1051769294.HKD","LU1831875114.USD","LU1515016050.SGD","BK4079","CSTA.U","CYTK","LU0359202008.SGD","LU1188198961.HKD","BK4588","LU0173614495.USD","LU0651946864.USD","BEKE","BK4505","LU1023057109.AUD","LU1688375341.USD","LU0244354667.USD","BK4504","BK4548","BK4509","BK4139","BK4526","LU1051768304.USD","LU0287142896.SGD","LU0326950275.SGD","BK4585","LU0651947912.USD"],"gpt_icon":0},{"id":"1141869495","title":"Cytokinetics公布Maple-HCM研究主要结果，在2025年欧洲心脏病学会大会发表并刊登于《新英格兰医学杂志》","url":"https://stock-news.laohu8.com/highlight/detail?id=1141869495","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141869495?lang=zh_cn&edition=full","pubTime":"2025-08-30 15:20","pubTimestamp":1756538435,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布了其Maple-HCM研究的主要结果，相关数据已在2025年欧洲心脏病学会大会上进行了展示，同时研究成果也已发表在权威医学期刊《新英格兰医学杂志》上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK","BK4139","BK4588","BK4505","BK4585"],"gpt_icon":0},{"id":"1100177896","title":"Cytokinetics：接受阿菲卡坦治疗的患者中51%在NYHA功能分级上有一个或多个等级改善，而接受美托洛尔治疗的患者仅为26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100177896","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100177896?lang=zh_cn&edition=full","pubTime":"2025-08-30 15:20","pubTimestamp":1756538430,"startTime":"0","endTime":"0","summary":"Cytokinetics：接受阿菲卡坦治疗的患者中51%在NYHA功能分级上有一个或多个等级改善，而接受美托洛尔治疗的患者仅为26%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","CYTK","BK4139","BK4505","BK4588"],"gpt_icon":0},{"id":"1116510698","title":"Cytokinetics：积极试验结果显示Aficamten优于标准治疗药物β受体阻滞剂美托洛尔","url":"https://stock-news.laohu8.com/highlight/detail?id=1116510698","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116510698?lang=zh_cn&edition=full","pubTime":"2025-08-30 15:20","pubTimestamp":1756538428,"startTime":"0","endTime":"0","summary":"Cytokinetics：积极试验结果显示Aficamten优于标准治疗药物β受体阻滞剂美托洛尔","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","CYTK","BK4588","BK4585"],"gpt_icon":0},{"id":"1167884525","title":"Cytokinetics：与美托洛尔相比，Aficamten使NT-proBNP降低81%并显著改善左心房容积指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1167884525","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167884525?lang=zh_cn&edition=full","pubTime":"2025-08-30 15:20","pubTimestamp":1756538421,"startTime":"0","endTime":"0","summary":"Cytokinetics公司宣布，与美托洛尔相比，其药物Aficamten能够使NT-proBNP水平降低81%，并在左心房容积指数方面实现显著改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK","BK4585","BK4588","BK4505","BK4139"],"gpt_icon":0},{"id":"1107188140","title":"Cytokinetics宣布将在2025年欧洲心脏病学会大会上发表五项Aficamten相关研究报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1107188140","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107188140?lang=zh_cn&edition=full","pubTime":"2025-08-25 19:31","pubTimestamp":1756121493,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布将在2025年欧洲心脏病学会大会上发表五项与Aficamten相关的研究报告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","CYTK","BK4139","BK4505","BK4588"],"gpt_icon":0},{"id":"2555397038","title":"Cytokinetics, Incorporated盘中异动 早盘股价大涨5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555397038","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555397038?lang=zh_cn&edition=full","pubTime":"2025-07-31 22:17","pubTimestamp":1753971466,"startTime":"0","endTime":"0","summary":"北京时间2025年07月31日22时17分，Cytokinetics, Incorporated股票出现异动，股价急速拉升5.28%。Cytokinetics, Incorporated股票所在的生物技术行业中，整体涨幅为2.74%。Cytokinetics, Incorporated公司简介：细胞动力科技有限公司是一家后期生物技术公司，开发肌肉生物学驱动的治疗以肌肉功能降低、肌肉无力和疲劳为特征的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731221747a46dc641&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731221747a46dc641&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","BK4588","CYTK","BK4585"],"gpt_icon":0},{"id":"2550655742","title":"Cytokinetics, Incorporated盘中异动 股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550655742","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550655742?lang=zh_cn&edition=full","pubTime":"2025-07-09 22:24","pubTimestamp":1752071044,"startTime":"0","endTime":"0","summary":"北京时间2025年07月09日22时24分，Cytokinetics, Incorporated股票出现异动，股价大幅拉升5.05%。Cytokinetics, Incorporated股票所在的生物技术行业中，整体涨幅为1.29%。Cytokinetics, Incorporated公司简介：细胞动力科技有限公司是一家后期生物技术公司，开发肌肉生物学驱动的治疗以肌肉功能降低、肌肉无力和疲劳为特征的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709222404a4408f66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709222404a4408f66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CYTK","BK4588","BK4505","BK4139","BK4585"],"gpt_icon":0},{"id":"2517301014","title":"Cytokinetics, Incorporated2024财年实现净利润-5.90亿美元，同比减少12.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517301014","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517301014?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363247,"startTime":"0","endTime":"0","summary":"3月8日，Cytokinetics, Incorporated公布财报，公告显示公司2024财年净利润为-5.90亿美元，同比减少12.17%；其中营业收入为18.47百万美元，同比增加145.29%，每股基本收益为-5.26美元。从资产负债表来看，Cytokinetics, Incorporated总负债15.37亿美元，其中短期债务30.50百万美元，资产负债比为0.92，流动比率为6.16。机构评级：截至2025年3月8日，当前有20家机构对Cytokinetics, Incorporated目标价做出预测，其中目标均价为79.30美元，其中最低目标价为60.00美元，最高目标价为120.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000202a2647f1e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000202a2647f1e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CYTK"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cytokinetics.com","stockEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.038},{"period":"3month","weight":0.1282},{"period":"6month","weight":0.8332},{"period":"1year","weight":0.3508},{"period":"ytd","weight":0.3508}],"compareEarnings":[{"period":"1week","weight":-0.0123},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.019},{"period":"6month","weight":0.0905},{"period":"1year","weight":0.1635},{"period":"ytd","weight":0.1635}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cytokinetics, Incorporated于1997年8月5日成立，符合特拉华州的法律规定。它是一家处于临床阶段的生物制药公司，主要致力于为重大疾病和糟糕的医疗条件提供潜在的治疗方法的这样一种调节肌肉功能的新型小分子治疗方法的发现和发展。它目前处于发展阶段，着重于科研，开发药品筛选技术和融资。","yearOnYearQuotes":[{"month":1,"riseRate":0.47619,"avgChangeRate":0.002524},{"month":2,"riseRate":0.47619,"avgChangeRate":-0.024236},{"month":3,"riseRate":0.47619,"avgChangeRate":-0.003116},{"month":4,"riseRate":0.619048,"avgChangeRate":0.016608},{"month":5,"riseRate":0.590909,"avgChangeRate":0.01979},{"month":6,"riseRate":0.409091,"avgChangeRate":-0.000087},{"month":7,"riseRate":0.681818,"avgChangeRate":0.060358},{"month":8,"riseRate":0.636364,"avgChangeRate":0.040484},{"month":9,"riseRate":0.409091,"avgChangeRate":0.034179},{"month":10,"riseRate":0.318182,"avgChangeRate":-0.070805},{"month":11,"riseRate":0.5,"avgChangeRate":0.021311},{"month":12,"riseRate":0.454545,"avgChangeRate":0.096331}],"exchange":"NASDAQ","name":"Cytokinetics","nameEN":"Cytokinetics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cytokinetics(CYTK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cytokinetics(CYTK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cytokinetics,CYTK,Cytokinetics股票,Cytokinetics股票老虎,Cytokinetics股票老虎国际,Cytokinetics行情,Cytokinetics股票行情,Cytokinetics股价,Cytokinetics股市,Cytokinetics股票价格,Cytokinetics股票交易,Cytokinetics股票购买,Cytokinetics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cytokinetics(CYTK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cytokinetics(CYTK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}